Resources Contact Us Home
Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety

Image Number 13 for United States Patent #8119616.

The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a .beta.-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.

  Recently Added Patents
Methods and system for providing drug pricing information from multiple pharmacy benefit managers (PBMs)
Systems and methods for switching supply load current estimation
Build process management system
Therapeutic rinse in a self-heating package
Systems, methods, and apparatus to prepare a mobile device for provisioning
Electric power steering apparatus
System for thermally controlling displays
  Randomly Featured Patents
Self tightening chuck with an axial lock
Multi-ratio transmission
Filter driver to enumerate smartcard nodes for plug and play
Roller blind system, in particular for a sunroof
Woven stretchable grounding strap
Calibration of load indicator for ergometric exerciser
Pervasively data parallel information handling system and methodology for generating data parallel select operations
Radiopaque marker for a surgical sponge
Electrically erasable programmable logic device